title: [Autologous hematopoietic stem cell transplantation followed by oral bexarotene in a patient with advanced mycosis fungoides].
abstract: We describe the case of a 17-year-old patient with rapidly progressing and aggressive mycosis fungoides, with multiple cutaneous tumors and large cell transformation. She was initially treated with 3 cycles of high-dose chemotherapy with mega-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) without response, leading to the decision to undertake autologous hematopoietic stem cell transplantation. Partial remission of the disease was achieved with this treatment and subsequent introduction of oral bexarotene led to complete remission, which has been maintained for more than 3 years with good tolerance of oral therapy. We discuss the advantages and disadvantages of autologous hematopoietic stem cell transplantation and the use of oral bexarotene.
authors.affiliation: Servicio de Dermatología. Hospital de Cruces. Baracaldo. Vizcaya. España. spbarrio@hotmail.com
authors.forename: S
authors.initials: S
authors.lastname: Pérez-Barrio
authors.forename: R
authors.initials: R
authors.lastname: Izu
authors.forename: J C
authors.initials: JC
authors.lastname: García-Ruiz
authors.forename: E
authors.initials: E
authors.lastname: Acebo
authors.forename: Z
authors.initials: Z
authors.lastname: Martínez de Lagrán
authors.forename: J L
authors.initials: JL
authors.lastname: Díaz-Pérez
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D000077610:Bexarotene; D002066:Busulfan / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008466:Mechlorethamine / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D009182:Mycosis Fungoides / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D011701:PUVA Therapy; D036102:Peripheral Blood Stem Cell Transplantation; D011241:Prednisone / Q000008:administration & dosage; D011994:Recombinant Proteins; D012074:Remission Induction; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013764:Tetrahydronaphthalenes; D003561:Cytarabine; D008466:Mechlorethamine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D000077610:Bexarotene; D002066:Busulfan; D002945:Cisplatin; D011241:Prednisone; D008775:Methylprednisolone